Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

Size: px
Start display at page:

Download "Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management"

Transcription

1 Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (625) Measure Code: PRS Rule : Applicable Provider Specialty: General Criteria Summary Steward: Active Health Management Lab Data: Y Percentage of males with prostate cancer that have had their PSA monitored in the past 12 months Urology, Oncology, Internal Medicine, Family Practice, Geriatric Medicine, 1. Measurement period: 1 year prior to measurement period end date 2. Continuous enrollment: 3. Anchor date: measurement period end date (ie. December 31 of calendar year) 4. Gaps in enrollment: One 45-day gap allowed in the measurement year 5. Medical coverage: Yes 6. Drug coverage: No 7. Attribution time frame: 1 year on all prostate cancer denominator events 8. Exclusions apply: Yes 9. Age range: 18 years or older as of the beginning of the measurement year Summary of changes for 2014 No changes Denominator : All male patients, 18 years or older as of the beginning of the measurement year with a diagnosis of prostate cancer any time prior to or during the measurement year Inclusion Criteria: All male patients, 18 years or older as of the beginning of the measurement year with a diagnosis of prostate cancer any time prior to or during the measurement year Eligibility Criteria Age is 18 years or older Age in Years >= 18 As of the beginning of measurement year Page 1

2 Claim Criteria Diagnosis of prostate cancer 1 Any Diagnosis Code = Prostate Cancer Value Set Any time prior to or during the measurement year Exclusion Criteria: Patients with prostate cancer treatment at any time during the measurement year OR Patients with diagnosis of metastatic disease during the measurement year OR Patients who have been in a skilled nursing facility during the measurement year Prostate Cancer treatment 1 (CPT Procedure Code = Prostate Cancer Treatment Value Set ICD 9 Procedure Codes = Prostate Cancer Treatment Value Set) OR Diagnosis of metastasis OR Patients in Skilled Nursing Facility 1 Any Diagnosis Code = Metastasis Value Set 1 (CPT Procedure Code = Skilled Nursing Facility Value Set UB Rev Code = Skilled Nursing Facility Value Set 1 Place of service code = Skilled Nursing Facility Value Set) Page 2

3 Continuous Enrollment Criteria: Continuous enrollment AND Has medical coverage Continuous Enrollment is 12 out of 12 months Coverage Indicator Medical = Y Numerator : Males in the denominator who had PSA monitoring anytime during the measurement year. Inclusion Criteria: Males in the denominator who had PSA monitoring anytime during the measurement year. PSA monitoring 1 CPT Procedure Code = PSA Monitoring Value Set HCPCS code = ICD-9 Diagnosis = LOINC codes = Page 3

4 Notes: Appendix Prostate Cancer Value Set Code Code Type 185 ICD-9-CM Diagnosis Malignant neoplasm of prostate Prostate Cancer Value Set Code Code Type CPT Prostatectomy, perineal, subtotal CPT Extensive Prostate Surgery CPT Extensive Prostate Surgery CPT Extensive Prostate Surgery CPT Removal of Prostate CPT Removal of Prostate CPT Extensive Prostate Surgery CPT Extensive Prostate Surgery CPT Extensive Prostate Surgery CPT Percut/Needle Insert - Pros CPT Surgical Exposure - Prostate CPT Extensive Prostate Surgery CPT Extensive Prostate Surgery CPT Laparo Radical Prostatectomy CPT Infuse Radioactive Materials CPT Apply Intrcav Radiat Simple Page 4

5 77762 CPT Apply Intrcav Radiat Interm CPT Apply Interstit Radiat Simpl CPT Apply Interstit Radiat Inter CPT Apply Interstit Radiat Compl CPT High Intensity Brachytherapy CPT High Intensity Brachytherapy CPT High Intensity Brachytherapy CPT High Intensity Brachytherapy CPT Radium/Radioisotope Therapy G0256 CPT Prostate brachytherapy implanting Palladium seeds G0261 CPT Prostate brachytherapy implanting iodine seeds 4164F CPT Adjuvant hormonal therapy 4200F CPT Prostate external beam radiotherapy as primary therapy 4201F CPT Prostate external beam radiotherapy to non-prostate only 60.3 ICD-9-PCS Procedure Suprapubic prostatectomy 60.4 ICD-9-PCS Procedure Retropubic prostatectomy 60.5 ICD-9-PCS Procedure Radical prostatectomy 60.6 ICD-9-PCS Procedure Other prostatectomy ICD-9-PCS Procedure Local excision of lesion of prostate ICD-9-PCS Procedure Perineal prostatectomy ICD-9-PCS Procedure Other prostatectomy Metastasis Value Set Code Code Type 1970* ICD-9-CM Diagnosis Secondary Malig Neo Lung 1971* ICD-9-CM Diagnosis Sec Mal Neo Mediastinum 1972* ICD-9-CM Diagnosis Second Malig Neo Pleura 1973* ICD-9-CM Diagnosis Sec Malig Neo Resp NEC 1974* ICD-9-CM Diagnosis Sec Malig Neo Sm Bowel 1975* ICD-9-CM Diagnosis Sec Malig Neo Lg Bowel Page 5

6 1976* ICD-9-CM Diagnosis Sec Mal Neo Peritoneum 1977* ICD-9-CM Diagnosis Second Malig Neo Liver 1978* ICD-9-CM Diagnosis Sec Mal Neo GI NEC 1980* ICD-9-CM Diagnosis Second Malig Neo Kidney 1981* ICD-9-CM Diagnosis Sec Malig Neo Urin NEC 1982* ICD-9-CM Diagnosis Secondary Malig Neo Skin 1983* ICD-9-CM Diagnosis Sec Mal Neo Brain/Spine 1984* ICD-9-CM Diagnosis Sec Malig Neo Nerve NEC 1985* ICD-9-CM Diagnosis Secondary Malig Neo Bone 1986* ICD-9-CM Diagnosis Second Malig Neo Ovary 1987* ICD-9-CM Diagnosis Second Malig Neo Adrenal 1988* ICD-9-CM Diagnosis Second Malig Other Specified Sites Skilled Nursing Facility Value Set Code Code Type CPT Nursing Facility Care - Init CPT Nursing Fac Care - Subseq CPT Nursing Fac Discharge Day CPT Annual Nursing Fac Assessmnt 055* UB Revenue Skilled Nursing 31 Place of Service Skilled Nursing Facility Code Code Type CPT Assay of Psa - Complexed CPT Assay of Psa - Total CPT Assay of Psa - Free G0103 HCPCS Psa - Total Screening ICD-9-CM Diagnosis Elvtd Prstate Spcf Antgn Page 6

7 LOINC Prostate specific Ag LOINC Prostate specific Ag.free LOINC Prostate specific Ag.free/Prostate specific Ag.total , LOINC Prostate specific Ag , LOINC Prostate specific Ag.free LOINC Prostate specific Ag.protein bound LOINC Prostate specific Ag Page 7

Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management Measure : Prostate Cancer: Cancer Surveillance Owner: NQF (625) Measure Code: PRS Rule : Applicable Provider Specialty: General Criteria Summary Steward: Active Health Management Lab Data: Y Percentage

More information

Oncology, Colorectal Surgery, Gastroenterology, Internal Medicine, Family Practice, General Surgery, Geriatric Medicine, Multispecialty

Oncology, Colorectal Surgery, Gastroenterology, Internal Medicine, Family Practice, General Surgery, Geriatric Medicine, Multispecialty Measure : Follow-Up After Initial Diagnosis and Treatment Of Colorectal Cancer: Colonoscopy Owner: NQF (#0572) Measure Code: CLF Lab Data: N Steward: Health Benchmarks-IMS Health Rule Description: Percentage

More information

NCQA that the exclusion still applies.

NCQA that the exclusion still applies. Measure Name: Pharyngitis Treatment for Children Owner: NCQA (CWP) Measure Code: PHR Lab Data: Y Rule Description: The percentage of children 2-18 years of age who were diagnosed with pharyngitis, dispensed

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS

More information

Date Modified: May 29, Clinical Quality Measures for PQRS

Date Modified: May 29, Clinical Quality Measures for PQRS Date Modified: May 29, 2014 Clinical Quality s for PQRS # Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3

More information

Date Modified: March 31, Clinical Quality Measures for PQRS

Date Modified: March 31, Clinical Quality Measures for PQRS Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process

More information

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures 2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

Radiotherapy Of Prostate Cancer

Radiotherapy Of Prostate Cancer Radiotherapy Of Prostate Cancer 1 / 6 2 / 6 3 / 6 Radiotherapy Of Prostate Cancer We compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized

More information

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Chapter 18: Glossary

Chapter 18: Glossary Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is

More information

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Coding Companion for Oncology/Hematology. A comprehensive illustrated guide to coding and reimbursement

Coding Companion for Oncology/Hematology. A comprehensive illustrated guide to coding and reimbursement Coding Companion for Oncology/Hematology A comprehensive illustrated guide to coding and reimbursement Contents Getting Started with Coding Companion... i General/Integumentary...1 Musculoskeletal...36

More information

COLORECTAL CANCER SCREENING

COLORECTAL CANCER SCREENING COLORECTAL CANCER SCREENING APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA ACCEPTED CODES DOCUMENTATION REQUIREMENTS What documentation

More information

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist Identifying Initial Populations and Sampling for OCM and EBRT Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist January 22, 2015 Learning Objectives Help participants to understand

More information

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES OVERVIEW Diagnosis Laboratory Tests PSA Free and Total PSA PCA-3 4K Score The

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage

More information

Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION:

More information

Patient Identification Quiz

Patient Identification Quiz Patient Identification Quiz 1. A patient presents to your facility for the first time on 1/1/2009. At that time he has a history of lymphoma (9590/3), melanoma (8720/3) and meningioma (9530/0). These three

More information

MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER

MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Measure Description. Denominator Statement

Measure Description. Denominator Statement CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic

More information

Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Measure Specifications Measure Description

Measure Specifications Measure Description CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

Physician Self-Referral: Recent Research from the Government Accountability Office (GAO)

Physician Self-Referral: Recent Research from the Government Accountability Office (GAO) Physician Self-Referral: Recent Research from the Government Accountability Office (GAO) James C. Cosgrove, Ph.D. National Health Policy Forum July 18, 2014 Self-Referral: Background Physician self-referral

More information

BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Table of Contents Data Supplement 1: Additional Evidence Table(s) Table

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH Quality of Life After Modern Treatment Options I will be presenting some recently published data on the quality of life after modern treatment options for prostate cancer. My name is Dr. Ronald Chen. I'm

More information

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

How ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA

How ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA How ICD-10 Affects Radiation Oncology Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA ICD-10 ICD-10-CM has added new challenges to the radiation oncology specialty. Approximately 220 ICD-9-CM codes

More information

NATIONAL QUALITY FORUM

NATIONAL QUALITY FORUM Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES:

More information

TOOKAD (padeliporfin) Patient Information Guide

TOOKAD (padeliporfin) Patient Information Guide TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 QUALITY PERFORMANCE METRIC CALCULATION QUALITY METRICS SELECTED FOR MEASUREMENT Per Section 3.2 of the Agreement, HCPP must meet the following

More information

The European Board of Urology

The European Board of Urology Page 1 of 15 The European Board of Urology Sub-specialty certification application: Prostate cancer, A - General information A1 - APPLICATION IDENTIFICATION 1a. Application code blank 1b. EBU internal

More information

LDR prostate brachytherapy

LDR prostate brachytherapy LDR prostate brachytherapy Introduction Low dose rate (LDR) prostate brachytherapy is a modern, effective minimally invasive treatment appropriate for many men with early prostate cancer. I perform this

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process Measure #226 (NQF 0028): Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention National Quality Strategy Domain: Community / Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES:

More information

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

NCD for Medicine: Human Chorionic Gonadotropin(190.27)

NCD for Medicine: Human Chorionic Gonadotropin(190.27) Codes from CPSI Code Listing that Support Medical Necessity **Choose a corresponding ICD9 code from the corresponding group that the CPT code resides in when selecting a code that supports Medical Necessity.

More information

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting

More information

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Percentage of patients who underwent endoscopic procedures following SWL

Percentage of patients who underwent endoscopic procedures following SWL Non-QPP Measures Measure ID Measure Title Definition Type Domain 1 AQUA12 Benign Prostate Hyperplasia: IPSS improvement after diagnosis Percentage of patients with NEW diagnosis of clinically significant

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Prostate Cancer in men with germline DNA repair deficiency

Prostate Cancer in men with germline DNA repair deficiency Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,

More information

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY

More information

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process Measure. #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2017

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2018

More information

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care

Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care Measure #72 (NQF 0385): Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY

More information

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden

More information

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

One Stop Prostate Biopsy Protocol Author Consultation Date Approved One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA /9/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #5: NCRA 2017-044 5/9/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate

More information

Troubleshooting Audio

Troubleshooting Audio Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want

More information

Prostate cancer. Treatments Side effects and management in the community setting

Prostate cancer. Treatments Side effects and management in the community setting Prostate cancer Treatments Side effects and management in the community setting Kristoffer Ohlin CNS Urology Janice Minter Lead Cancer Nurse St George s Hospital Agenda Prostate cancer treatments Radiotherapy

More information

Non-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys

Non-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Non-QPP Measures # Measure Title Definition Type Domain 1 Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Percentage of patients (boys) =< 18 years of age newly diagnosed with undescended

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

creatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed

creatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed Non-QPP Measures # Measure Title Definition Type Domain 1 Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys Percentage of patients (boys) =< 18 years of age newly diagnosed with undescended

More information

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer. Description Measure 0221: Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (Commission on Cancer, American College of Surgeons) Percentage of patients presenting with

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:

More information

Newer Aspects of Prostate Cancer Underwriting

Newer Aspects of Prostate Cancer Underwriting Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions

More information

Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care

Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome Measure #445 (NQF 0119): Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG) National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320 Quality ID #147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical

More information

Prostate Cancer Update 2017

Prostate Cancer Update 2017 Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

Cryosurgical Ablation of Breast Fibroadenomas

Cryosurgical Ablation of Breast Fibroadenomas Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Project Overview Ronald C. Chen, MD MPH Introductions Principal Investigator: Ronald C. Chen, MD MPH ACS Staff: Eileen Tonner,

More information

Faster Cancer Treatment Indicators: Use cases

Faster Cancer Treatment Indicators: Use cases Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools

More information

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date MP 8.01.11 Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Revised

More information

2014 Oncology Measures Group Overview

2014 Oncology Measures Group Overview 2014 Oncology Measures Group Overview The Oncology Measures Group is a reporting option that significantly reduces the burden of participation in the Physician Quality Reporting System (PQRS). Source:

More information

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018 Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from

More information

Tobacco Use: Screening & Cessation Intervention

Tobacco Use: Screening & Cessation Intervention Tobacco Use: Screening and Cessation Intervention MSSP ACO Measure Tobacco Use: Screening & Cessation Intervention Domain: Preventive Care and Screening ACO 17 PREV- 10 PQRS - 226 NQF 0028 Measure Steward:

More information

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network

Community care of Prostate Cancer. Shaun Costello Southern Cancer Network Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return

More information

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends Prostate Cancer: Low Dose Rate (Seed) Brachytherapy Information for patients, families and friends About this booklet This booklet is designed to give you information about low dose-rate (seed) brachytherapy

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of

MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #22 (NQF 0271): Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures) National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Measure #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

Measure Information Form

Measure Information Form Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure ID#: SCIP- Performance

More information

The Selenium and Vitamin E Prevention Trial

The Selenium and Vitamin E Prevention Trial The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

AllinaHealthSystems 1

AllinaHealthSystems 1 2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology

More information